Plamotamab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Plamotamab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Phase 1
Highest phase
3
Registered trials
7
Result records
3
Matched deals
Executive recommendation: HOLD / OPTION
Decision memo
Preserve optionality until clinical differentiation, transaction economics, and freedom-to-operate are sufficiently de-risked.
The central underwriting question is whether Plamotamab can convert its Bispecific T-cell Engager (BiTE) profile and CD20 x CD3 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Plamotamab (query alias: Plamotamab) |
|---|---|
| Modality / target | Bispecific T-cell Engager (BiTE); CD20 x CD3; CD20 inhibitors, CD3 stimulants, CD20-directed cytolytic effects |
| Highest global status | Phase 1 |
| Originator | Xencor, Inc. |
| Active developers | Xencor, Inc., Novartis Pharma AG |
The MCP disease footprint includes Rheumatoid Arthritis, B-Cell Lymphoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT05328102 | Phase 2 | Terminated | 3 | Part 1 A: Number of Participants With Treatment Emergent Adverse Events (TEAEs) |
| NCT02924402 | Phase 1 | Completed | 154 | Safety and tolerability as determined by the number of participants with treatment-related adverse events as assessed by CTCAE v4.03 |
| NCT07230353 | Phase 1 | Recruiting | 68 | Primary |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Plamotamab: First Presentation of Subcutaneous Administration in a Phase 1 Dose Escalation Study in Heavily Pretreated R/R NHL Patients Who Had Prior CAR-T Cell Therapy
Phase 1; n=22; evaluation: Positive. Reported fields: CRS = CRS was the most common TEAE (68%, (Gr 1, 54%; Gr 2, 14%) ; CRS = CRS was the most common TEAE (68%, (Gr 1, 54%; Gr 2, 14%) ; CRS = CRS was the most common TEAE (68%, (Gr 1, 54%; Gr 2, 14%)
3105Risk Factors for Severe Infection in Patients Receiving Bispecific Antibody Therapies for Lymphoma
Not Applicable; n=not disclosed; evaluation: not stated. Reported fields: Adverse Event: PJP infection = 3 patients had PJP infection of which 1 patient was on prophylaxis ; Adverse Event: PJP infection = 3 patients had PJP infection of which 1 patient was on prophylaxis ; Adverse Event: PJP infection = 3 patients had PJP infection of which 1 patient was on prophylaxis
A Phase 2 Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of XmAb13676 (Plamotamab) Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Phase 2; n=3; evaluation: not stated. Reported fields: Part 1 A: Number of Participants With Treatment Emergent Adverse Events (TEAEs) = 3 Participants ; -; -
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Plamotamab addresses Rheumatoid Arthritis, B-Cell Lymphoma. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Bispecific T-cell Engager (BiTE)—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2020-12-04 | Xencor and Janssen partner to explore, advance, and market CD28 bispecific antibodies using the XmAb platform for global treatment of prostate cancer. | Phase 1 | US$100.0M upfront; US$1,180.0M milestones |
| 2019-01-07 | Xencor will regain the ex-U.S. commercial rights to XmAb13676, a CD20 x CD3 bispecific antibody, from Novartis | Phase 1 | Financial terms not disclosed |
| 2010-06-27 | MorphoSys and Xencor Sign License and Collaboration Agreement for Clinical Antibody Program | Approved | US$13.0M upfront |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “NK cell engager proteins comprising Anti-CD20 and ant-nkp46 antibody, linked to il-2 in treatment of r/r b-nhl”. The milestone feed surfaced a patent-application signal described as “Dosing of a bispecific antibody that binds CD20 and CD3”. The milestone feed surfaced a patent-application signal described as “Bispecific antibodies that bind CD20 and CD3”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Cytokine-release syndrome, neurotoxicity, and infection
- Durability after deep B-cell or plasma-cell depletion
- Dose-step-up logistics, manufacturing, and outpatient feasibility
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
HOLD / OPTION
Preserve optionality until clinical differentiation, transaction economics, and freedom-to-operate are sufficiently de-risked.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
